Aurobindo Pharma Q1: Analysts expect profit at Rs 75 cr

Aurobindo Pharma is set to announce its results for the quarter ended June 2012 today. Analysts on an average expect the company to report profit after tax of around Rs 75 crore during the quarter as against loss of Rs 122 crore in a year ago period, but the PAT is likely to fall by 30.55% quarter-on-quarter.

Reported loss in the April-June quarter of financial year 2011-12 was due to the redemption premium charged to the P&L of Rs 320 crore. The company had redeemed foreign currency convertible bonds (FCCBs) worth USD 139 million in that quarter. After adjusting this item, the profit after tax stood at Rs 107 crore in the Q1FY12.

Revenues are seen going up by 16.4% YoY and 5% QoQ to Rs 1,254 crore during the quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to go up by 17% and 36% QoQ to Rs 191 crore.

Operating profit margin is likely to be flat year-on-year at 15.2%, but the same is seen rising by 320 basis points quarter-on-quarter

Analysts expect growth to be led by US and Europe regions. US business will be led by launch of Combivir & Plavix generic.

Foreign exchange gain/loss have not incorporated, hence that could impact the bottomline.